Top

Published in:

Open Access 01-12-2019 | Statins | Research article

Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study

Authors: Erin J. A. Bowles, Onchee Yu, Rebecca Ziebell, Lu Chen, Denise M. Boudreau, Debra P. Ritzwoller, Rebecca A. Hubbard, Jennifer M. Boggs, Andrea N. Burnett-Hartman, Andrew Sterrett, Monica Fujii, Jessica Chubak

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Cardiovascular medications may be associated with cancer development, but little is known about their association with cancer recurrence. Medications such as statins and antihypertensives may be commonly used among colon cancer survivors, who are, on average, diagnosed in their mid-60s. We described the associations between statins and antihypertensive medications and colon cancer recurrence in a large, population-based study.

Methods

We conducted a cohort study among adults with stage I-IIIA colon cancer diagnosed in 1995–2014 in two Kaiser Permanente regions, Colorado and Washington. Statin and antihypertensive use were obtained from electronic pharmacy dispensing data. People were classified as medication users on the date of their first dispensing after cohort entry, which started 90 days after completing cancer treatment, continuing through the earliest of death, health plan disenrollment, or chart abstraction. We collected outcome information from medical record abstraction and tumor registries on colon cancer recurrences and second primary cancers. Using Cox proportional hazards multivariable models, we estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for colon cancer recurrences and any cancer event (recurrences and new primaries at any anatomic site) comparing medication users to non-users.

Results

Among 2039 people, 937 (46%) used statins and 1425 (70%) used antihypertensives at any point during a median of 4.9 years of follow-up; 460 people had any additional cancer event, including 152 with a colon cancer recurrence. Statin use was not associated with colon cancer recurrence (HR = 1.09, 95%CI = 0.65–1.85) or any cancer event (HR = 1.12, 95%CI = 0.85–1.47), nor was antihypertensive use associated with recurrence (HR = 0.73, 95%CI = 0.44–1.21) or any cancer event (HR = 0.93, 95%CI = 0.70–1.24).

Conclusions

Our results suggest no association between cardiovascular medication use and the risk of recurrence or any additional cancer, and may provide reassurance to colon cancer survivors.

American Cancer Society Facts and Figures [October 25, 2017]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.

SEER [October 25, 2017]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html.

Morbidity and Mortality Weekly Report [March 10, 2018]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6447a1.htm#tab1.

Lim SY. Role of statins in coronary artery disease. Chonnam Med J. 2013;49(1):1–6. https://doi.org/10.4068/cmj.2013.49.1.1 Epub Apr 25.CrossRefPubMedPubMedCentral

Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508–19. https://doi.org/10.1038/sj.leu.2402476.CrossRefPubMed

Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10–9.PubMed

Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer. 2005;5(12):930–42. https://doi.org/10.1038/nrc751.CrossRefPubMed

Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001;22(8):1139–48.CrossRef

Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 2001;61(12):4885–91.PubMed

10.

Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 2001;7(7):2067–75.PubMed

11.

Siddiqui AA, Nazario H, Mahgoub A, Patel M, Cipher D, Spechler SJ. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci. 2009;54(6):1307–11. https://doi.org/10.1007/s10620-009-0790-8 Epub 2009 Apr 1.CrossRefPubMed

12.

Lakha F, Theodoratou E, Farrington SM, Tenesa A, Cetnarskyj R, Din FV, et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer. 2012;12:487. https://doi.org/10.1186/1471-2407-12-487.CrossRefPubMedPubMedCentral

13.

Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 2014;32(28):3177–83. https://doi.org/10.1200/JCO.2013.54.4569 Epub 2014 Aug 4.CrossRefPubMed

14.

Hoffmeister M, Jansen L, Rudolph A, Toth C, Kloor M, Roth W, et al. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst. 2015;107(6):djv045. https://doi.org/10.1093/jnci/djv045 Print 2015 Jun.CrossRefPubMed

15.

Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Dannenberg AJ, et al. Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer. J Clin Oncol. 2016;34(30):3664-3671.

16.

Yokomichi H, Nagai A, Hirata M, Tamakoshi A, Kiyohara Y, Kamatani Y, et al. Statin use and all-cause and cancer mortality: BioBank Japan cohort. J Epidemiol. 2017;87(1):11–20.

17.

Gray RT, Loughrey MB, Bankhead P, Cardwell CR, McQuaid S, O'Neill RF, et al. Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. Br J Cancer. 2017;116(12):1652–9. https://doi.org/10.1038/bjc.2017.139 Epub May 18.CrossRefPubMedPubMedCentral

18.

Lash TL, Riis AH, Ostenfeld EB, Erichsen R, Vyberg M, Ahern TP, et al. Associations of statin use with colorectal Cancer recurrence and mortality in a Danish cohort. Am J Epidemiol. 2017;186(6):679–87. https://doi.org/10.1093/aje/kww245.CrossRefPubMed

19.

Voorneveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, Zanders MMJ, et al. Statin Use After Diagnosis of Colon Cancer and Patient Survival. Gastroenterology. 2017;153(2):470–9.e4. https://doi.org/10.1053/j.gastro.2017.05.011 Epub May 13.CrossRefPubMed

20.

Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011;103(20):1540–51. https://doi.org/10.1093/jnci/djr307 Epub 2011 Aug 17.CrossRefPubMedPubMedCentral

21.

Centers for Disease Control and Prevention [March 23, 2018]. Available from: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_disease.htm.

22.

Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23(10):623–35. https://doi.org/10.1038/jhh.2009.21. Epub Apr 2

23.

Molteni A, Ward WF, Ts'ao CH, Taylor J, Small W Jr, Brizio-Molteni L, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des. 2003;9(9):751–61.CrossRef

24.

Fitzgerald PJ. Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol. 2010;2:1–3.PubMedPubMedCentral

25.

Fitzgerald PJ. Is norepinephrine an etiological factor in some types of cancer? Int J Cancer. 2009;124(2):257–63. https://doi.org/10.1002/ijc.24063.CrossRefPubMed

26.

Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628–38. https://doi.org/10.18632/oncotarget.101009.CrossRefPubMedPubMedCentral

27.

Jansen L, Weberpals J, Kuiper JG, Vissers PAJ, Wolkewitz M, Hoffmeister M, et al. Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: results from a population-based study. Int J Cancer. 2017;141(1):62–71. https://doi.org/10.1002/ijc.30717.CrossRefPubMed

28.

Engineer DR, Burney BO, Hayes TG, Garcia JM. Exposure to ACEI/ARB and beta-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced Colon Cancer. Transl Oncol. 2013;6(5):539–45 eCollection 2013.CrossRef

29.

Heinzerling JH, Anthony T, Livingston EH, Huerta S. Predictors of distant metastasis and mortality in patients with stage II colorectal cancer. Am Surg. 2007;73(3):230–8.PubMed

30.

Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(11 Suppl):3109S–20S. https://doi.org/10.1093/jn/131.11.3109S.CrossRefPubMed

31.

Fair AM, Montgomery K. Energy balance, physical activity, and cancer risk. Methods Mol Biol. 2009;472:57–88. https://doi.org/10.1007/978-1-60327-492-0_3.CrossRefPubMed

32.

Howes LG, Edwards CT. Calcium antagonists and cancer. Is there really a link? Drug Saf. 1998;18(1):1–7.CrossRef

33.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

34.

Health Care Systems Research Network Oakland, CA: Kaiser Permanente Division of Research (Northern California); 2015 [Available from: http://www.hcsrn.org/en/.

35.

Chubak J, Ziebell R, Greenlee RT, Honda S, Hornbrook MC, Epstein M, et al. The Cancer research network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations. Cancer Causes Control. 2016;27(11):1315–23.CrossRef

36.

Ross TR, Ng D, Brown JS, Pardee R, Hornbrook MC, Hart G, et al. The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. EGEMS. 2014;2(1):1049.CrossRef

37.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef

38.

Emilsson L, Garcia-Albeniz X, Logan RW, Caniglia EC, Kalager M, Hernan MA. Examining Bias in studies of statin treatment and survival in patients with Cancer. JAMA Oncol. 2018;4(1):63–70.CrossRef

39.

Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens. 2015;22:7.CrossRef

40.

Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314.CrossRef

Title: Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study
Authors: Erin J. A. Bowles
Onchee Yu
Rebecca Ziebell
Lu Chen
Denise M. Boudreau
Debra P. Ritzwoller
Rebecca A. Hubbard
Jennifer M. Boggs
Andrea N. Burnett-Hartman
Andrew Sterrett
Monica Fujii
Jessica Chubak
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Statins
Colon Cancer
Colon Cancer
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5493-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Is there a sex difference in postoperative prognosis of hepatocellular carcinoma?

Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis

BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review

β2AR-HIF-1α-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells

Failure patterns after curative resection for intrahepatic cholangiocarcinoma: possible implications for postoperative radiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer